Clinical Trials Browser

Phase 3 × Interventional × Everolimus × Clear all

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT03049189 2026-04-06

COMPETE

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

Advanced Breast Cancer

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 3 Active not recruiting

Seizures, Tuberous Sclerosis

NCT07405164 2026-03-31

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT05476939 2026-02-05

BIOMEDE 2

Phase 3 Recruiting

Diffuse Intrinsic Pontine Glioma

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT00799188 2025-12-19

CERTICOEUR

Phase 3 Completed

Skin Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

Breast Neoplasms

NCT01120249 2025-09-16

S0931

Phase 3 Completed

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT01805271 2025-05-14

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Phase 3 Active not recruiting

Primary Non-metastatic Breast Cancer

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 2 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03839940 2025-01-29

MIST

Phase 3 Terminated

39 enrolled 18 charts

Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01668784 2022-08-09

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Phase 3 Completed

821 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT01524783 2021-08-05

RADIANT-4

Phase 3 Completed

302 enrolled 16 charts

Neuroendocrine Tumors

NCT01865747 2021-04-27

METEOR

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

NCT03095040 2021-02-08

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Phase 3 Unknown

Renal Cell Cancer Metastatic

NCT02137837 2021-01-28

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Phase 3 Terminated

37 enrolled 16 charts

Breast Neoplasms

NCT02511639 2020-12-03

MAIN-A

Phase 3 Completed

Breast Cancer Metastatic

NCT03176238 2020-04-07

EVEREXES

Phase 3 Completed

235 enrolled 11 charts

Breast Neoplasms

NCT01248403 2020-01-29

AIO-STO-0111

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT02376985 2019-10-21

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Phase 3 Completed

Breast Neoplasms

NCT01198158 2019-03-06

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Phase 3 Terminated

77 enrolled 11 charts

Carcinoma, Renal Cell

NCT00876395 2018-12-19

BOLERO-1

Phase 3 Completed

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02134899 2018-12-10

EVERKYSTE

Phase 3 Completed

Cysts, Fibrosis, Polycystic Kidney, Autosomal Dominant

NCT01713946 2018-11-07

EXIST-3

Phase 3 Completed

366 enrolled 38 charts 2 FDA

Tuberous Sclerosis Complex-associated Refractory Seizures

NCT03580239 2018-07-09

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Phase 3 Unknown

Prostatic Neoplasms

NCT00790036 2017-07-12

PILLAR2

Phase 3 Completed

742 enrolled 10 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT00863655 2017-05-02

BOLERO-2

Phase 3 Completed

724 enrolled 20 charts

Breast Neoplasms

NCT01007942 2017-04-05

BOLERO-3

Phase 3 Completed

569 enrolled 16 charts

Breast Neoplasms

NCT01626222 2017-02-23

MACS2096

Phase 3 Completed

Breast Neoplasms

NCT00790400 2017-02-17

EXIST-2

Phase 3 Completed

118 enrolled 15 charts

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

NCT01035229 2016-09-22

EVOLVE-1

Phase 3 Completed

546 enrolled 18 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT02404051 2016-06-15

FEVEX

Phase 3 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT00567554 2016-02-10

GeparQuinto

Phase 3 Completed

Breast Neoplasms

NCT01773460 2016-02-10

Evelyn

Phase 3 Terminated

Breast Neoplasms

NCT00789828 2016-02-03

EXIST-1

Phase 3 Completed

117 enrolled 15 charts

Astrocytoma, Tuberous Sclerosis

NCT00879333 2015-11-03

GRANITE-1

Phase 3 Completed

656 enrolled 15 charts

Gastrointestinal

Digestive System Neoplasms, Stomach Diseases, Stomach Neoplasms